Immunologic treatment of Alzheimer's disease

New England Journal of Medicine

Volumn 341, Issue 22, 1999, Pages 1694-1695

  Blass, John P ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 2; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; HUMAN; IMMUNOTHERAPY; MEMORY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; BRAIN DISEASES; HUMANS; IMMUNIZATION; MICE; MICE, TRANSGENIC;

EID: 0033604587     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199911253412213     Document Type: Article

References (5)

1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
2. Seabrook GR, Smith DW, Bowery BJ, et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 1999;38:349-59.
3. Blass JP, Poirier J. Etiological hypotheses. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1995:17-31.
4. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-88.
5. Guo Q, Sebastian L, Sopher BL, et al. Increased vulnerability of hippocampal neurons from prescnilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem 1999;72:1019-29.